Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MHLW Collecting Evidence to Discuss Introduction of Medical Fee for Hospital Formularies in FY2022 Reimbursement Reform
The Ministry of Health, Labor and Welfare (MHLW) is preparing the evidence needed to discuss hospital formularies in preparation for the FY2022 medical fee revision. Its study group is working out a standard procedure for developing hospital formularies and plans…
To read the full story
Related Article
- No Chuikyo Members Call for Formulary Incentives under Medical Fee Schedule
December 9, 2021
- Spread of Regional Formularies Will Depend on “Human Relationships and Consensus-Building”: Professor
July 26, 2021
- Wariness Brewing within MHLW for Medical Fee to Incentivize Hospital Formularies
July 21, 2021
- Japan Forgoes Creation of Medical Fee to Reward Hospital Formularies in 2020 Reform
January 16, 2020
REGULATORY
- Japan Cabinet Approves National MCM Strategy to Boost Pandemic Response
March 25, 2026
- Pharma Urges Govt Support as Iran War Shows Early Impact on Supply Chains
March 25, 2026
- Japan Panel Slams MHLW’s 80% Single-IRB Target as Too Low
March 24, 2026
- Ishin Proposes Macroeconomic Indexing for Healthcare as LDP Talks Resume
March 24, 2026
- Japan OKs Bayer’s MRI Agent, Haihe’s PI3Kα Med, Enhertu’s Tumor-Agnostic Use, and More
March 24, 2026
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…